-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-522475-28-00
5
Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
-
2024-516646-19-00
5
2025-08-15
Type 2 diabetic patients with no prior cardiovascular (CV) events
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-519048-33-00
10
2025-11-25
resected pancreatic adenocarcinoma
-
2023-508785-16-00
5
2025-10-17
Very preterm neonate (gestational age at birth < 32 WG) with corrected
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2024-511442-39-00
5
2025-02-05
Rheumatoid arthritis (RA)
-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2023-508260-30-01
5
2024-07-30
Patients with poor prognostic OVARian cancers based on the tumor prima
-
2024-515788-73-00
4
2024-07-30
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IM
-
2024-512872-36-00
5
2024-07-25
obstetric_pathological delivery
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2024-515146-16-00
5
2023-05-15
Colorectal surgery
-
2024-511005-39-00
10
2022-06-22
Raynaud phenomenon